

EntroGen releases lung cancer RNA panel

March 2019—EntroGen announced the availability of a lung cancer RNA panel intended for the qualitative detection of *ALK*, *ROS1*, and *RET* fusion genes, as well as MET exon 14 skipping mutations in human lung RNA.

The one-step reverse transcriptase PCR assay combines first-strand cDNA synthesis and subsequent amplification of mutant and reference genes, designed to minimize hands-on time and reduce the risk of introducing contaminants during preamplification. The three-step workflow produces results in less than two hours and detects 47 variants in eight reactions, the company reports.

The panel is compatible with several multichannel real-time PCR instruments capable of detecting FAM, VIC, and CY5 fluorescent probes and comes with complimentary data analysis software to automate reporting. The panel is for research use only.

[EntroGen](#), 818-716-1070